Dr. Jean-Yves Blay on Eribulin in Leiomyosarcoma

Jean-Yves Blay, MD, PhD
Published Online: Monday, Oct 17, 2016


Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses a subgroup analysis of leiomyosarcoma patients from a phase III study of eribulin compared to dacarbazine (DTIC) in patients with advanced liposarcoma or leiomysosarcoma.
 
Leiomyosarcoma is a complex and difficult to treat patient population, says Blay. The analysis found that eribulin was equivalent to DTIC in terms of overall survival and progression-free survival in all subgroups of leiomyosarcoma. This is important because leiomyosarcoma is very heterogeneous, says Blay.
 
DTIC is well known to be a very active agent in leiomyosarcoma, so the observation that eribulin is equivalent is very interesting for the drug, he says.
 
Eribulin was well tolerated in leiomyosarcoma patients overall.
 

Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses a subgroup analysis of leiomyosarcoma patients from a phase III study of eribulin compared to dacarbazine (DTIC) in patients with advanced liposarcoma or leiomysosarcoma.
 
Leiomyosarcoma is a complex and difficult to treat patient population, says Blay. The analysis found that eribulin was equivalent to DTIC in terms of overall survival and progression-free survival in all subgroups of leiomyosarcoma. This is important because leiomyosarcoma is very heterogeneous, says Blay.
 
DTIC is well known to be a very active agent in leiomyosarcoma, so the observation that eribulin is equivalent is very interesting for the drug, he says.
 
Eribulin was well tolerated in leiomyosarcoma patients overall.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Optimizing Treatment and Management of Soft Tissue Sarcoma in Community OncologyNov 30, 20171.5
Publication Bottom Border
Border Publication
$emailPop$